Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Neurobiology of Aging|September 13, 2019
Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohortThomas Desmidt, Julien Delrieu, Thibaud Lebouvier, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 21, 2020
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapiesGiovanni B Frisoni, José Luis Molinuevo, Daniele Altomare, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 7, 2024
Integrative Multimodal Metabolomics to Early Predict Cognitive Decline Among Amyloid Positive Community-Dwelling Older AdultsMarie Tremblay-Franco, Cécile Canlet, Audrey Carriere, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 16, 2023
Cerebral Metabolic Signature of Chronic Benzodiazepine Use in Nondemented Older Adults: An FDG-PET Study in the MEMENTO CohortQuentin Gallet, Vincent Bouteloup, Maxime Locatelli, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 11, 2021
Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohortQuentin Gallet, Vincent Bouteloup, Maxime Locatelli, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 16, 2020
Clinical relevance of brain atrophy subtypes categorization in memory clinicsVincent Planche, Vincent Bouteloup, Jean-François Mangin, et al.
Alzheimer'S Research & Therapy|January 8, 2020
Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settingsLisa Vermunt, Graciela Muniz-Terrera, Lea Ter Meulen, et al.
European Journal of Neurology|June 24, 2025
Utility, Costs and Cost-Utility of Amyloid-PET in the Diagnostic Process of Memory Clinic Patients: A Trial-Based Economic Evaluation From AMYPAD-DPMSIngrid S van Maurik, Daniele Altomare, Lyduine E Collij, et al.
Neurology|February 20, 2024
Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer DiseaseMerle Hönig, Daniele Altomare, Camilla Caprioglio, et al.
JAMA Neurology|May 8, 2023
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical TrialDaniele Altomare, Frederik Barkhof, Camilla Caprioglio, et al.
Pageof 6